Finished pharmaceutical dosage form of a methenamine salt such as methenamine mandelate
US10639312B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Dec 6, 2019 |
| Grant date | May 5, 2020 |
| Priority date | — |
| Expiry date | Dec 6, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention contemplates a high dose finished pharmaceutical dosage form comprising a methenamine salt, such as methenamine mandelate, as an active pharmaceutical ingredient wherein the methenamine salt API has a moisture content that is less than the upper limit specified in the USP. A preferred embodiment of the present invention has a moisture content that is half of the limit set forth in the USP for each particular methenamine salt. An even more preferred embodiment has a moisture content of less than or equal to one-tenth of a percent (0.1%), regardless of the methenamine salt. The present invention may include one or more pharmaceutically acceptable ingredients. The present invention also contemplates a moisture content of the high dose finished pharmaceutical dosage form that is less than one percent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.